
Abingworth
Abingworth invests in life science and biopharma companies across all stages of product development, spanning seed and early stage, development stage (including VIPEs and public markets), and clinical co-development. The firm focuses on biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, specialty pharma, and platform technologies, primarily in the US and Europe.
Based on data we found publicly online. Real numbers may be higher.
What they back
Industries
#1
85%
Biotechnology
22 companies
#2
4%
Clean Technology
1 companies
#3
4%
Construction Technology
1 companies
- 4Enterprise Software3.8%
- 5Healthcare Technology3.8%
Companies can be in several industries.
Based on data we found publicly online. Real numbers may be higher.
Portfolio composition
Companies by founding year
Peak: 2018: 3 companies
Based on data we found publicly online. Real numbers may be higher.
How they invest
Deal profile
Check size
Min
$15M
Typical
$22.5M
Max
$30M
Based on data we found publicly online. Real numbers may be higher.
Based on data we found publicly online. Real numbers may be higher.
Fund details
Funds
Based on data we found publicly online. Real numbers may be higher.